Secondary analysis of phase III NSABP B-41 (221 patients with HER2+ breast cancer): an image-derived immune signature, DeSTIL, identified 61 patients with better EFS on trastuzumab vs the combination arm (HR 0.09); no EFS difference in 160 signature-negative patients.
Secondary analysisn = 221
Bharadwaj et al. Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation